Safety and PK of BI 1323495 in Healthy Japanese Subjects

Phase 1, randomised, single-blind trial of BI 1323495 in Non-cystic fibrosis bronchiectasis (NCFB), cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) (11 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Participants With Drug-related Adverse Events (AEs) up to 17 days, Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 Extrapolated to Infinity and 1 more. Started Nov 2020; status: completed.